Tao-Tao Tang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7286059/publications.pdf

Version: 2024-02-01

22	1,871	623734 14	752698 20
papers	citations	h-index	g-index

23	23	23	2180
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tubular-specific CDK12 knockout causes a defect in urine concentration due to premature cleavage of the slc12a1 gene. Molecular Therapy, 2022, , .	8.2	0
2	High phosphorus mediated the release of Câ€Xâ€C motif chemokine ligand 8 in valvular interstitial cellsâ€induced endothelialâ€toâ€mesenchymal transition via miRâ€214/phosphatase and tensin homolog to promote valvular calcification in chronic kidney disease. Clinical and Translational Medicine, 2022, 12, .	4.0	0
3	Extracellular vesicles for renal therapeutics: State of the art and future perspective. Journal of Controlled Release, 2022, 349, 32-50.	9.9	20
4	FIH-1-modulated HIF-1Î± C-TAD promotes acute kidney injury to chronic kidney disease progression via regulating KLF5 signaling. Acta Pharmacologica Sinica, 2021, 42, 2106-2119.	6.1	9
5	Kim-1 Targeted Extracellular Vesicles: A New Therapeutic Platform for RNAi to Treat AKI. Journal of the American Society of Nephrology: JASN, 2021, 32, 2467-2483.	6.1	50
6	VDR/Atg3 Axis Regulates Slit Diaphragm to Tight Junction Transition via p62-Mediated Autophagy Pathway in Diabetic Nephropathy. Diabetes, 2021, 70, 2639-2651.	0.6	14
7	SAP130 released by damaged tubule drives necroinflammation via miRNA-219c/Mincle signaling in acute kidney injury. Cell Death and Disease, 2021, 12, 866.	6.3	14
8	Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury. Theranostics, 2021, 11, 5248-5266.	10.0	122
9	Exosomal miRNA-19b-3p of tubular epithelial cells promotes M1 macrophage activation in kidney injury. Cell Death and Differentiation, 2020, 27, 210-226.	11.2	232
10	Extracellular vesicle-based Nanotherapeutics: Emerging frontiers in anti-inflammatory therapy. Theranostics, 2020, 10, 8111-8129.	10.0	67
11	Extracellular vesicleâ€“encapsulated IL-10 as novel nanotherapeutics against ischemic AKI. Science Advances, 2020, 6, eaaz0748.	10.3	147
12	Integrin, Exosome and Kidney Disease. Frontiers in Physiology, 2020, 11, 627800.	2.8	12
13	Extracellular Vesicles: Opportunities and Challenges for the Treatment of Renal Fibrosis. Advances in Experimental Medicine and Biology, 2019, 1165, 693-709.	1.6	12
14	Employing Macrophage-Derived Microvesicle for Kidney-Targeted Delivery of Dexamethasone: An Efficient Therapeutic Strategy against Renal Inflammation and Fibrosis. Theranostics, 2019, 9, 4740-4755.	10.0	112
15	Extracellular Vesicles: Opportunities and Challenges for the Treatment of Renal Diseases. Frontiers in Physiology, 2019, 10, 226.	2.8	56
16	HIF-1Î± inducing exosomal microRNA-23a expression mediates the cross-talk between tubular epithelial cells and macrophages in tubulointerstitial inflammation. Kidney International, 2019, 95, 388-404.	5.2	147
17	New insight into the role of extracellular vesicles in kidney disease. Journal of Cellular and Molecular Medicine, 2019, 23, 731-739.	3.6	60
18	Cinacalcet attenuated bone loss via inhibiting parathyroid hormone-induced endothelial-to-adipocyte transition in chronic kidney disease rats. Annals of Translational Medicine, 2019, 7, 312-312.	1.7	5

#	Article	IF	Citations
19	Therapeutic application of extracellular vesicles in kidney disease: promises and challenges. Journal of Cellular and Molecular Medicine, 2018, 22, 728-737.	3.6	62
20	Hydroxychloroquine attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation. Cell Death and Disease, 2018, 9, 351.	6.3	139
21	Renal tubule injury: a driving force toward chronic kidney disease. Kidney International, 2018, 93, 568-579.	5.2	504
22	Megalin/Cubulin-Lysosome-mediated Albumin Reabsorption Is Involved in the Tubular Cell Activation of NLRP3 Inflammasome and Tubulointerstitial Inflammation. Journal of Biological Chemistry, 2015, 290, 18018-18028.	3.4	87